BamSEC and AlphaSense Join Forces
Learn More

Karyopharm Therapeutics Inc. – Material Contracts

Formerly NASDAQ: KPTI
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.3
from 10-Q 23 pages Registration Rights Agreement
12/34/56
EX-10.2
from 8-K 22 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 41 pages Securities Purchase Agreement
12/34/56
EX-10.37
from 10-K 5 pages October 8, 2025 Delivered by Email
12/34/56
EX-10.35
from 10-K 5 pages October 7, 2025 Delivered by Email Richard Paulson Dear Richard
12/34/56
EX-10.32
from 10-K 5 pages October 7, 2025 Delivered by Email Sohanya Cheng Dear Sohanya
12/34/56
EX-10.28
from 10-K 5 pages October 7, 2025 Delivered by Email Lori Macomber Dear Lori
12/34/56
EX-10.25
from 10-K 8 pages Karyopharm Therapeutics Inc. Annual Bonus Plan Most Recently Approved by the Board of Directors on December 12, 2025
12/34/56
EX-10.12
from 10-Q 3 pages Amendment No. 4 to License Agreement by and Between Karyopharm Therapeutics Inc. and Berlin-Chemie AG
12/34/56
EX-10.11
from 10-Q 7 pages Fourth Amendment to Revenue Interest Financing Agreement
12/34/56
EX-10.10
from 10-Q 7 pages Third Amendment to Revenue Interest Financing Agreement
12/34/56
EX-10.9
from 8-K 27 pages Registration Rights Agreement
12/34/56
EX-10.8
from 8-K 23 pages Form of Registration Rights Agreement Among the Initial Investors Party Hereto and Karyopharm Therapeutics Inc. Dated as of October 10, 2025 Registration Rights Agreement
12/34/56
EX-10.7
from 8-K 33 pages Securities Purchase Agreement
12/34/56
EX-10.6
from 8-K 103 pages Sixth Amendment to Revenue Interest Financing Agreement
12/34/56
EX-10.5
from 8-K 22 pages October 7, 2025 Karyopharm Therapeutics Inc. 85 Wells Avenue, Suite 210 Newton, Ma 02459 Attention: Chief Financial Officer Re: Exchange of Karyopharm Therapeutics Inc. 3.00% Convertible Senior Notes Due 2025 for Common Stock, Warrants to Purchase Common Stock and Pre-Funded Warrants to Purchase Common Stock Ladies and Gentlemen
12/34/56
EX-10.4
from 8-K 22 pages October 7, 2025 Karyopharm Therapeutics Inc. 85 Wells Avenue, Suite 210 Newton, Ma 02459 Attention: Chief Financial Officer Re: Exchange of Karyopharm Therapeutics Inc. 6.00% Convertible Senior Notes Due 2029 for Common Stock and Pre-Funded Warrants to Purchase Common Stock Ladies and Gentlemen
12/34/56
EX-10.3
from 8-K 28 pages October 7, 2025 Karyopharm Therapeutics Inc. 85 Wells Avenue, Suite 210 Newton, Ma 02459 Attention: Chief Financial Officer Re: Exchange for Karyopharm Therapeutics Inc. 9.00% Convertible Senior Notes Due 2029 and New Warrants to Purchase Common Stock Ladies and Gentlemen
12/34/56
EX-10.2
from 8-K 29 pages $15,000,000 of 9.00% Convertible Senior Notes Due 2028 Issued by Karyopharm Therapeutics Inc. Note Purchase Agreement
12/34/56
EX-10.1
from 10-Q 4 pages June 30, 2025 Re: License Agreement
12/34/56